Home › NDC Lookup › RxCUI directory › RxCUI 1720271

0.7 ML asfotase alfa 40 MG/ML Injection — RxCUI 1720271

RxNorm drug concept · Semantic clinical drug
RxCUI 1720271 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1720271
Official name0.7 ML asfotase alfa 40 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asasfotase alfa 28 MG per 0.7 ML Injection; asfotase alfa 28 MG in 0.7 ML Injection
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)1,368 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Asfotase Alfa: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Hypophosphatasia (HPP) is a rare genetic disorder where the body doesn't make enough of an enzyme called TNSALP. Without that enzyme, bones can't harden properly, which causes prob...
  • What exactly is hypophosphatasia and why does my child need this medication?
  • Strensiq is injected under the skin — not given as a pill or IV. Most patients inject it either three or six times per week, depending on what your prescriber decides works best. Y...
  • How often does Strensiq need to be injected, and where on the body?
📖 Read our full Asfotase Alfa guide →

🕸️ Concept Web — How 0.7 ML asfotase alfa 40 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 0.7 ML asfotase alfa 40 MG/ML Injection RxCUI 1720271

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Asfotase alfa 1720259
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Strensiq 1720264
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Asfotase alfa Injection 1720262
    • Asfotase alfa Injectable Product 1720261
    • Asfotase alfa Injection [Strensiq] 1720266
    • Strensiq Injectable Product 1720267
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Asfotase alfa 40 MG/ML SCDC · 1720260
  • Asfotase alfa Injection SCDF · 1720262
  • Asfotase alfa Injectable Product SCDG · 1720261

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 1720271 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
25682-0010-12 12 VIAL in 1 CARTON (25682-010-12) / .45 mL in 1 VIAL (2568... STRENSIQ Alexion Pharmaceuticals, Inc. 2015-10-23
25682-0013-12 12 VIAL in 1 CARTON (25682-013-12) / .7 mL in 1 VIAL (25682... STRENSIQ Alexion Pharmaceuticals, Inc. 2015-10-23
25682-0016-12 12 VIAL in 1 CARTON (25682-016-12) / 1 mL in 1 VIAL (25682-... STRENSIQ Alexion Pharmaceuticals, Inc. 2015-10-23
25682-0019-12 12 VIAL in 1 CARTON (25682-019-12) / .8 mL in 1 VIAL (25682... STRENSIQ Alexion Pharmaceuticals, Inc. 2015-10-23
Observed labelers: Alexion Pharmaceuticals, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.